NCT06910124
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06910124
Title Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dickran Kazandjian, MD
Indications
Therapies
Age Groups: adult | child | senior
Covered Countries USA


No variant requirements are available.